Developing a Potent Microtubule-Targeting Agent with Less Toxicity

Developing a Potent Microtubule-Targeting Agent with Less Toxicity

Diazon Pharmaceuticals is developing DZ-2384, which targets a proven therapeutic pathway in oncology, but with less toxicity than existing agents, as demonstrated in a preclinical study published November 2016 in Science Translational Medicine by researchers at McGill University in Canada.

No Comments

Post A Comment